Media stories about Genomic Health (NASDAQ:GHDX) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Genomic Health earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 47.4210549417572 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Genomic Health (NASDAQ GHDX) opened at $29.25 on Thursday. Genomic Health has a twelve month low of $26.37 and a twelve month high of $34.02.

GHDX has been the subject of several recent analyst reports. Jefferies Group LLC restated a “hold” rating and issued a $34.00 price target on shares of Genomic Health in a research note on Friday, October 20th. Cowen and Company reiterated a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a report on Friday, September 1st. BidaskClub upgraded Genomic Health from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Canaccord Genuity lowered their price objective on Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 15th. Finally, Piper Jaffray Companies reiterated a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $32.67.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Genomic Health (GHDX) Share Price” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/22/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-genomic-health-ghdx-share-price.html.

In other news, insider James J. Vaughn sold 1,379 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total transaction of $44,831.29. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kimberly J. Popovits sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $31.00, for a total value of $155,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,379 shares of company stock worth $676,131. Insiders own 46.20% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.